Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Increased basal ganglia b… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy.

Artikel i vetenskaplig tidskrift
Författare Ruben Smith
Martin Schain
Christer Nilsson
Olof Strandberg
Tomas Olsson
Douglas Hägerström
Jonas Jögi
Edilio Borroni
Michael Schöll
Michael Honer
Oskar Hansson
Publicerad i Movement disorders : official journal of the Movement Disorder Society
Volym 32
Nummer/häfte 1
Sidor 108-114
ISSN 1531-8257
Publiceringsår 2017
Publicerad vid Institutionen för neurovetenskap och fysiologi
Sidor 108-114
Språk en
Länkar dx.doi.org/10.1002/mds.26813
www.ncbi.nlm.nih.gov/entrez/query.f...
Ämneskategorier Medicinsk bioteknologi, Klinisk medicin

Sammanfattning

Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently developed tau PET tracers may improve the diagnostic work-up of PSP.Regional tau accumulation was studied using (18) F-AV-1451 PET in 11 patients with PSP and 11 age-matched healthy controls in the Swedish BioFinder study.(18) F-AV-1451 standard uptake volume ratios were significantly higher in the basal ganglia in PSP patients when compared with controls (globus pallidus 1.75 vs 1.50; putamen 1.51 vs 1.35). Retention in the basal ganglia was correlated with age in both groups (r = .43-.78, P < .05). In PSP, we observed a significant correlation between clinical deterioration measured with the PSP rating scale and standard uptake volume ratios in the globus pallidus (r = .74, P < .05). However, no (18) F-AV-1451 retention was observed in the cerebral cortex or white matter of either PSP patients or controls, and autoradiography did not reveal any specific binding of AV-1451 to PSP tau aggregates.We found higher (18) F-AV-1451 retention in the basal ganglia of PSP patients when compared with healthy elderly controls, but also increases with age in both controls and patients. As a result of the overlap in retention between diagnostic groups and the age-dependent increase present also in controls, (18) F-AV-1451 PET might not reliably distinguish individual patients with PSP from controls. However, further studies are needed to evaluate whether (18) F-AV-1451 PET might be useful as a progression marker in clinical PSP trials. © The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?